Stephen Hennigar

Stephen Hennigar


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2018 in The Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
SHStephen Hennigar
Stephen Hennigar
HLHarris R Lieberman
Harris R Lieberman
VFVictor L Fulgoni
Victor L Fulgoni
JMJames P McClung
James P McClung
Serum zinc concentration is used to assess the zinc status of populations. Cutoffs for serum zinc were developed on the basis of data from the second NHANES (1976–1980). The objective of this study was to evaluate serum zinc concentrations in the US population and to determine factors affecting serum zinc with the use of NHANES 2011–2014. Serum zinc was determined in males and females aged ≥6 y with the use of NHANES 2011–2014 (n = 4347). Dietary zinc intake was determined, and factors affecting serum zinc were identified with the use of regression models adjusting for sex, age, fasting status, and time of blood draw. ORs were calculated to identify factors associated with the risk of being below the serum zinc cutoff, and the prevalence of low serum zinc in the US was calculated. P < 0.01 was considered significant. Mean ± SE serum zinc concentrations in males and females were 84.9 ± 0.8 and 80.6 ± 0.6 μg/dL, respectively (P < 0.0001). Regression models with serum zinc as the dependent variable indicated that afternoon and evening blood draws (β = –9.7 and –15.3; P < 0.0001) were negatively associated with serum zinc concentrations and serum albumin (β = 16.1; P < 0.0001) and hemoglobin (β = 1.0; P = 0.0048) were positively associated with serum zinc concentrations. Hypoalbuminemia (OR = 11.2; 99% CI: 3.4, 37.3), anemia in females (OR: 3.4; 99% CI: 1.7, 6.9), and pregnancy (OR: 9.6; 99% CI: 2.9, 31.9) increased the odds of being below the serum zinc cutoff (P < 0.0001 for all). Zinc from diet or supplements did not affect serum zinc (P > 0.01). Approximately 3.8% of children (<10 y), 8.6% of males (≥10 y), and 8.2% of females (≥10 y) were below the serum zinc cutoff. Factors such as sex, age, and time of blood draw should be considered when using serum zinc concentration to determine the zinc status of a population. Caution is advised when interpreting serum zinc concentration in populations with a high prevalence of hypoalbuminemia or anemia. This trial was registered at http://www.isrctn.com as ISRCTN96013840.

19 September 2017 in The FASEB Journal
Verified
Journal Article
Closed access
PDF file
SHStephen Hennigar
Stephen Hennigar
JMJames P. McClung
James P. McClung
SPStefan M. Pasiakos
Stefan M. Pasiakos

1 February 2021 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
SHStephen Hennigar
Stephen Hennigar
JMJames P. McClung
James P. McClung
AHAdrienne Hatch-McChesney
Adrienne Hatch-McChesney
JAJillian T. Allen
Jillian T. Allen
MWMarques A. Wilson
Marques A. Wilson
SPStefan M. Pasiakos
Stefan M. Pasiakos
Strenuous physical activity promotes inflammation and depletes muscle glycogen, which may increase the iron regulatory hormone hepcidin. Hepcidin reduces dietary iron absorption and may contribute to declines in iron status frequently observed following strenuous physical activity. To determine the effects of strenuous physical activity on hepcidin and dietary iron absorption and whether energy deficit compared with energy balance modifies those effects. This was a randomized, cross-over, controlled-feeding trial in healthy male subjects (n = 10, mean ± SD age: 22.4 ± 5.4 y, weight: 87.3 ± 10.9 kg) with sufficient iron status (serum ferritin 77.0 ± 36.7 ng/mL). Rest measurements were collected before participants began a 72-h simulated sustained military operation (SUSOPS), designed to elicit high energy expenditure, glycogen depletion, and inflammation, followed by a 7-d recovery period. Two 72-h SUSOPS trials were performed where participants were randomly assigned to consume either energy matched (±10%) to their individual estimated total daily energy expenditure (BAL) or energy at 45% of total daily energy expenditure to induce energy deficit (DEF). On the rest day and at the completion of BAL and DEF, participants consumed a beverage containing 3.8 mg of a stable iron isotope, and plasma isotope appearance was measured over 6 h. Muscle glycogen declined during DEF and was preserved during BAL (-188 ± 179 mmol/kg, P-adjusted < 0.01). Despite similar increases in interleukin-6, plasma hepcidin increased during DEF but not BAL, such that hepcidin was 108% greater during DEF compared with BAL (7.8 ± 12.2 ng/mL, P-adjusted < 0.0001). Peak plasma isotope appearance at 120 min was 74% lower with DEF (59 ± 38% change from 0 min) and 49% lower with BAL (117 ± 81%) compared with rest (230 ± 97%, P-adjusted < 0.01 for all comparisons). Strenuous physical activity decreases dietary iron absorption compared with rest. Energy deficit exacerbates both the hepcidin response to physical activity and declines in dietary iron absorption compared with energy balance. This trial was registered at clinicaltrials.gov as NCT03524690.

2 January 2020 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
SHStephen Hennigar
Stephen Hennigar
CBClaire E Berryman
Claire E Berryman
MHMelissa N Harris
Melissa N Harris
JKJ Philip Karl
J Philip Karl
HLHarris R Lieberman
Harris R Lieberman
SPStefan M Pasiakos
Stefan M Pasiakos
Context: Severe energy deprivation markedly inhibits erythropoiesis by restricting iron availability for hemoglobin synthesis. Objective: The objective of this study was to determine whether testosterone supplementation during energy deficit increased indicators of iron turnover and attenuated the decline in erythropoiesis compared to placebo. Design: This was a 3-phase, randomized, double-blind, placebo-controlled trial. Setting: The study was conducted at the Pennington Biomedical Research Center. Patients or Other Participants: Fifty healthy young males. Intervention(s): Phase 1 was a 14-day free-living eucaloric controlled-feeding phase; phase 2 was a 28-day inpatient phase where participants were randomized to 200 mg testosterone enanthate/week or an isovolumetric placebo/week during an energy deficit of 55% of total daily energy expenditure; phase 3 was a 14-day free-living, ad libitum recovery period. Main Outcome Measure(s): Indices of erythropoiesis, iron status, and hepcidin and erythroferrone were determined. Results: Hepcidin declined by 41%, indicators of iron turnover increased, and functional iron stores were reduced with testosterone administration during energy deficit compared to placebo. Testosterone administration during energy deficit increased circulating concentrations of erythropoietin and maintained erythropoiesis, as indicated by an attenuation in the decline in hemoglobin and hematocrit with placebo. Erythroferrone did not differ between groups, suggesting that the reduction in hepcidin with testosterone occurs through an erythroferrone-independent mechanism. Conclusion: These findings indicate that testosterone suppresses hepcidin, through either direct or indirect mechanisms, to increase iron turnover and maintain erythropoiesis during severe energy deficit. This trial was registered at www.clinicaltrials.gov as #NCT02734238.

23 July 2022 in The Journal of Physiology
Verified
Journal Article
Closed access
LMLee Margolis
Lee Margolis
AHAdrienne Hatch-McChesney
Adrienne Hatch-McChesney
JAJillian T. Allen
Jillian T. Allen
MDMarissa N. DiBella
Marissa N. DiBella
CCChristopher T. Carrigan
Christopher T. Carrigan
SPStefan M. Pasiakos
Stefan M. Pasiakos

23 July 2020 in British Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
SHStephen Hennigar
Stephen Hennigar
AKAlyssa M. Kelley
Alyssa M. Kelley
BABradley J. Anderson
Bradley J. Anderson
NANicholes J. Armstrong
Nicholes J. Armstrong
HMHolly Lehmann McClung
Holly Lehmann McClung
JMJames P. McClung
James P. McClung
Zn is an essential nutrient for humans; however, a sensitive biomarker to assess Zn status has not been identified. The objective of this study was to determine the reliability and sensitivity of Zn transporter and metallothionein (MT) genes in peripheral blood mononuclear cells (PBMCs) to Zn exposureex vivoand to habitual Zn intake in human subjects. In study 1, human PBMCs were cultured for 24 h with 0–50 µmZnSO4with or without 5 µmN,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN), and mRNA expression ofSLC30A1-10,SLC39A1-14,MT1subtypes (A,B,E,F,G,H,L,MandX),MT2A,MT3andMT4mRNA was determined. In study 2, fifty-four healthy male and female volunteers (31·9 (sd13·8) years, BMI 25·7 (sd2·9) kg/m2) completed a FFQ, blood was collected, PBMCs were isolated and mRNA expression of selected Zn transporters and MT isoforms was determined. Study 1:MT1E,MT1F,MT1G,MT1H,MT1L,MT1M,MT1X,MT2AandSLC30A1increased with increasing concentrations of Zn and declined with the addition of TPEN. Study 2: Average daily Zn intake was 16·0 (sd5·3) mg/d (range: 9–31 mg/d), and plasma Zn concentrations were 15·5 (SD2·8) μmol/l (range 11–23 μmol/l). PBMCMT2Awas positively correlated with dietary Zn intake (r0·306,P= 0·03) and total Zn intake (r0·382,P< 0·01), whereas plasma Zn was not (P> 0·05 for both). Findings suggest thatMT2AmRNA in PBMCs reflects dietary Zn intake in healthy adults and may be a component in determining Zn status.